Longeveron Revenue and Competitors
Estimated Revenue & Valuation
- Longeveron's estimated annual revenue is currently $5.4M per year.
- Longeveron's estimated revenue per employee is $155,000
Employee Data
- Longeveron has 35 Employees.
Longeveron's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | General Counsel and Secretary | Reveal Email/Phone |
4 | VP, Manufacturing | Reveal Email/Phone |
5 | VP Business Operations | Reveal Email/Phone |
6 | VP, Business Operations | Reveal Email/Phone |
7 | Non-Executive Director | Reveal Email/Phone |
8 | Senior Director Patient Services | Reveal Email/Phone |
9 | Co-Founder and Chief Scientific Officer and Chairman | Reveal Email/Phone |
10 | Director, Clinical Operations and Medical Affairs | Reveal Email/Phone |
Longeveron Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $15.3M | 99 | 5% | N/A | N/A |
#2 | $1.1M | 7 | -30% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $4.3M | 28 | -3% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $2.5M | 16 | 7% | N/A | N/A |
#9 | $1.4M | 9 | -25% | N/A | N/A |
#10 | $0.6M | 4 | 0% | N/A | N/A |
What Is Longeveron?
We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. We are currently conducting Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer's disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS), which is the current exception to our focus on aging. Our mission is to advance Lomecel-B™ and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging – a period known as healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-B™ addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.
keywords:N/AN/A
Total Funding
35
Number of Employees
$5.4M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Longeveron News
Get Longeveron alerts: Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of...
April events to highlight Longeveron's commitment to developing cell therapeutics for chronic aging related diseases. April 14, 2022 08:58 ET | Source:...
About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.1M | 35 | -39% | N/A |
#2 | $4.1M | 35 | 3% | N/A |
#3 | $4.1M | 35 | N/A | N/A |
#4 | $3.9M | 35 | N/A | N/A |
#5 | $7.6M | 35 | 30% | N/A |